Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Taselisib · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Arm A \- Taselisib with Trastuzumab emtansine (also called T-DM1) * Taselisib administered orally, daily in each treatment cycle (3 weeks). * Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks). |
| Arm B | EXPERIMENTAL | Arm B -Taselisib with T-DM1 and Pertuzumab * Taselisib is administered oral, daily or every other day per treatment cycle (3 weeks). * Trastuzumab emtansine (also called T-DM1) administered once via IV per treatment cycle (3 weeks). * Pertuzumab- administered once via IV per treatment cycle (3 weeks). |
| Arm C | EXPERIMENTAL | Arm C: * Taselisib with Pertuzumab and Trastuzumab * Cohort C will not open without additional authorization from Genentech * Taselisib is administered oral, daily in each treatment cycle (3 weeks). * Trastuzumab administered once via IV per treatment cycle (3 weeks). * Pertuzumab- administered once via IV per treatment cycle (3 weeks). |
| Arm D | EXPERIMENTAL | Arm D * Taselisib with Pertuzumab, Trastuzumab, and Paclitaxel * Cohort will not be opened without additional authorization from Genentech * Taselisib- administered oral, daily in each treatment cycle (3 weeks). * Pertuzumab- administered once via IV per treatment cycle (3 weeks). * Trastuzumab administered once via IV per treatment cycle (3 weeks). * Paclitaxel- administered via IV, weekly for 3 weeks within each cycle. |
| Name | Type | Description |
|---|---|---|
| Taselisib | DRUG | - |
| Trastuzumab emtansine | DRUG | - |
| Pertuzumab | DRUG | - |
| Trastuzumab | DRUG | - |
| Paclitaxel | DRUG | - |
Inclusion Criteria: * Metastatic, locally advanced , or locally recurrent breast cancer * Histologically confirmed HER2+ invasive breast cancer * Measurable or non-measurable disease per RECIST v1.1 * Prior therapy - Prior trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1) are al...
Top 20 of 92 competitors
Taselisib is an investigational small molecule being studied for the treatment of Metastatic Breast Cancer, specifically in combination with anti-HER2 therapies for advanced HER2+ breast cancer. It is currently in Phase 1 clinical development and is not approved by the FDA.
Taselisib is a small molecule designed to target cancer cells in HER2+ breast cancer. It is being evaluated in combination with anti-HER2 therapies to treat advanced HER2+ breast cancer, including metastatic and recurrent forms of the disease.
Taselisib is being developed by SS Innovations International Inc., a company traded under the ticker symbol SSII. The drug is currently in Phase 1 clinical development for the treatment of Metastatic Breast Cancer.
Taselisib is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA and is still undergoing clinical trials to evaluate its safety and efficacy in patients with Metastatic Breast Cancer.
Taselisib has one completed clinical trial, NCT02390427, a Phase Ib dose-escalation study of Taselisib in combination with anti-HER2 therapies in participants with advanced HER2+ breast cancer. The trial enrolled 68 participants in the United States and is now completed.